A man has newly diagnosed metastatic hormone-relapsed prostate cancer. Chemotherapy is not clinically indicated, abiraterone is precluded by

Question

A man has newly diagnosed metastatic hormone-relapsed prostate cancer. Chemotherapy is not clinically indicated, abiraterone is precluded by uncontrolled mineralocorticoid toxicity, and no HRR mutation has been found. Which statement reflects NICE TA1130?

Accepted Answer

Offer talazoparib–enzalutamide; TA1130 does not require an HRR mutation

Answer

Treat with enzalutamide alone until progression before considering addition of a PARP inhibitor

Answer

Reserve talazoparib–enzalutamide for disease progressing after docetaxel and an androgen-receptor inhibitor

Answer

Use talazoparib monotherapy because abiraterone intolerance removes the need for androgen-receptor blockade

Answer

Exclude the combination because talazoparib requires a pathogenic BRCA1 or BRCA2 alteration

Prostate Cancer — SCE Medical Oncology MCQ

A man has newly diagnosed metastatic hormone-relapsed prostate cancer. Chemotherapy is not clinically indicated, abiraterone is precluded by uncontrolled mineralocorticoid toxicity, and no HRR mutation has been found. Which statement reflects NICE TA1130?